NCT05868265进行中（未招募）2 期
Neoadjuvant Enfortumab Vedotin in High-Grade Urothelial Carcinoma of the Upper Urinary Tract (Including Ureter and Renal Pelvis)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 9
- 试验地点
- 15
- 主要终点
- Proportion of patients who achieve pathologic complete response
研究概览
简要总结
The purpose of this study is to find out whether the study drug, enfortumab vedotin, is an effective and safe treatment for people who have urothelial carcinoma of the upper urinary tract. Study participants will be people who are not eligible to receive or have chosen not to receive the chemotherapy drug cisplatin for treatment of their cancer. In addition, all participants will be planning on having standard surgery to remove their tumor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed high grade urothelial carcinoma of the upper tract and/or radiographically visible tumor stage T2-T4a N0/x M0 disease with positive selective urinary cytology. Hydronephrosis associated with tumor on imaging or biopsy will be considered invasive by definition. (Variant histology is acceptable if there is a predominant urothelial component. Discussion with PI strongly encouraged.) Retroperitoneal lymph nodes <15 mm in the short axis will be eligible.
- •Patients who are
- •o Ineligible for cisplatin based on any of the following criteria:
- •Estimated or calculated creatinine clearance ≥ 30ml/min but < 60 ml/min
- •Grade 2 or above audiometric hearing loss (per CTCAE v5.0) or
- •Declined cisplatin-based neoadjuvant chemotherapy, as documented in medical chart
- •Availability of tumor specimen block, cell block or 30 unstained slides from diagnosis. Patients with fewer than 30 slides available may be enrolled after discussion with the Principal Investigator.Additional research biopsy is not required.
- •Karnofsky performance status ≥ 70%.
- •Medically appropriate candidate for radical surgery (nephroureterectomy, nephrectomy, or ureterectomy), as per treating Attending Urologic Oncologist
- •Age ≥ 18 years.
- •Required initial laboratory values:
- •Absolute neutrophil count ≥ 1.5 x 10^9 /L
- •Platelets ≥ 100 x 109 /L
- •Bilirubin ≤1.5 times the upper limit of normal (x ULN)
- •Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN PTT/PT ≤1.5 x ULN or INR < 1.7 x ULN for patients who are not receiving therapeutic anticoagulation. Patients receiving therapeutic anticoagulation should be on a stable dose
- •If patients are HIV (+) they are eligible as long as they have: cd4 >200, undetectable viral load and on HAART therapy.
排除标准
- •Presence of metastatic disease.
- •Prior treatment with systemic chemotherapy or radiotherapy for urothelial cancer of the bladder within the last 2 years. (Prior intravesical treatment such as BCG is allowed).
- •Grade 2 or higher peripheral neuropathy.
- •Patients with active keratitis or corneal ulcerations. Patients with superficial punctate keratitis are allowed if the disorder is being adequately treated in the opinion of the investigator.
- •Patients with uncontrolled diabetes. Uncontrolled diabetes is defined as hemoglobin A1c (HbA1c) ≥8% or HbA1c 7% to <8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained.
- •Unstable angina.
- •New York Heart Association (NYHA) Grade II or greater congestive heart failure.
- •History of myocardial infarction within 6 months.
- •History of stroke within 6 months.
- •Evidence of bleeding diathesis or coagulopathy. Therapeutic anticoagulation is permitted, but patients must be on a stable dose.
- •Major surgical procedure within 28 days prior to the study. (Transurethral resection of bladder tumor is permitted)
- •Serious, non-healing wound, ulcer, or bone fracture.
- •Patients with active tuberculosis.
- •Other prior malignancy active within the previous 2 years except for local or organ confined early stage cancer that has been definitively treated with curative intent or does not require treatment, does not require ongoing treatment, has no evidence of active disease, and has a negligible risk of recurrence and is therefore unlikely to interfere with the endpoints of the study.
- •Prior treatment with enfortumab vedotin or other MMAE-based antibody-drug conjugates (ADCs).
- •No known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
- •Women who are breastfeeding or pregnant as evidenced by a positive pregnancy test within 14 days of first dose.
- •Known severe (≥ Grade 3) hypersensitivity to enfortumab vedotin or to any excipient contained in the drug formulation of enfortumab vedotin (including histidine, trehalose dihydrate, and polysorbate 20).
- •Male subjects who are unwilling to use contraception during the treatment and for at least 31 weeks after the last dose of study treatment (5 half-lives of study drug plus 90 days duration of sperm turnover).
- •Women of childbearing potential (WOCBP) not using a medically acceptable means of contraception throughout the study treatment and for at least 23 weeks following the last dose of study treatment (5 half-lives of study drug plus 30 days duration of ovulatory cycle).
- •°WOCBP are defined as those who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal. Postmenopausal is defined as:
- •Amenorrhea ≥ 12 consecutive months without another cause, or
- •For women with irregular menstrual periods and on hormone replacement therapy (HRT), a documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL
- •Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.
- •Inability to comply with study and/or follow-up procedures.
研究组 & 干预措施
Enfortumab Vedotin
Experimental
All patients will receive enfortumab vedotin at 1.25 mg/kg on days 1 and 8 of 21 days cycle, for a total of three cycles, followed by radical nephroureterectomy, ureterectomy, or nephrectomy, depending on the site of the tumor and per the clinical decision of the treating urologist.
干预措施: Radical surgery (Procedure)
Enfortumab Vedotin
Experimental
All patients will receive enfortumab vedotin at 1.25 mg/kg on days 1 and 8 of 21 days cycle, for a total of three cycles, followed by radical nephroureterectomy, ureterectomy, or nephrectomy, depending on the site of the tumor and per the clinical decision of the treating urologist.
干预措施: Enfortumab Vedotin (Drug)
结局指标
主要结局
Proportion of patients who achieve pathologic complete response
时间窗: up to 2 years
The absence of residual disease on pathologic evaluation on surgical specimen following neoadjuvant enfortumab vedotin for UTUC. Pathologists will assess surgical specimens systematically using criteria agreed upon for all conventional neoadjuvant treatment based on the AJCC TNM staging system.
次要结局
- The rate of grade 3 - 4 toxicity(up to 2 years)
研究者
研究点 (15)
Loading locations...
相似试验
进行中（未招募）
2 期
Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE TrialLung CancerNon-small Cell Lung CancerNCT02664181Case Comprehensive Cancer Center13
进行中（未招募）
1 期
A study of enfortumab vedotin alone or in combination with other anticancer therapies for the treatment of urothelial cancerrothelial cancerMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046723Term: Urothelial carcinoma ureterSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046728Term: Urothelial carcinoma urethraSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10077840Term: Urothelial cancer of renal pelvisSystem Organ Class: 100000004864EUCTR2018-001527-39-ITSEAGEN INC.150
进行中（未招募）
1 期
A study of enfortumab vedotin alone or in combination with other anticancer therapies for the treatment of urothelial cancerrothelial cancerMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046723Term: Urothelial carcinoma ureterSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046728Term: Urothelial carcinoma urethraSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10077840Term: Urothelial cancer of renal pelvisSystem Organ Class: 100000004864EUCTR2018-001527-39-FRSeagen Inc.150
进行中（未招募）
1 期
A study of enfortumab vedotin alone or in combination with other anticancer therapies for the treatment of urothelial cancerrothelial cancerMedDRA version: 20.0Level: LLTClassification code: 10046714Term: Urothelial carcinoma bladder Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10046728Term: Urothelial carcinoma urethra Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10046723Term: Urothelial carcinoma ureter Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10077840Term: Urothelial cancer of renal pelvis Class: 10029104CTIS2023-503391-24-00Seagen Inc.355
进行中（未招募）
2 期
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)Locally Advanced or Metastatic Malignant Solid TumorsNCT04225117Astellas Pharma Global Development, Inc.329